Strides Shasun Expands Australia Base With Amneal Deal

05 Sep 2017

• By Penelope MacRae

Indian drug firm Strides Shasun has acquired the Australian unit of Amneal Pharmaceuticals, extending its customer footprint as it sets sights on becoming the leading player in the Australian generics market.

Leadership — STRIDES SHASUN HOPES TO ATTAIN A LEADERSHIP POSITION IN AUSTRALIA

Strides Shasun Ltd., which has been shifting gears to become a global business-to-consumer operation from being almost an entirely business-to-business company, has bought the Australian operations of Amneal Pharmaceuticals, pursuing its goal of being the leading player in the Australian generics market.

The purchase for AUD17m ($13m) was made by Arrow Pharmaceuticals, a unit of Strides Pharma Global Pte Ltd in Singapore,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

12 Jun 2025

• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

12 Jun 2025

• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.